HPV-Related Skin Phenotypes in Patients with Inborn Errors of Immunity.
HPV
inborn errors of immunity
skin
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
19
06
2022
revised:
23
07
2022
accepted:
24
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Patients with inborn errors of immunity (IEI) are prone to develop infections, either due to a broad spectrum of pathogens or to only one microbe. Since skin is a major barrier tissue, cutaneous infections are among the most prevalent in patients with IEI due to high exposures to many microbes. In the general population, human papillomaviruses (HPVs) cause asymptomatic or self-healing infections, but, in patients with IEI, unusual clinical expression of HPV infection is observed ranging from epidermodysplasia verruciformis (EV) (a rare disease due to β-HPVs) to profuse, persistent, and recalcitrant warts (due to α-, γ-, and μ-HPVs) or even tree man syndrome (due to HPV2). Mutations in EVER1, EVER2, and CIB1 are associated with EV phenotype; GATA2, CXCR4, and DOCK8 mutations are typically associated with extensive HPV infections, but there are several other IEI that are less frequently associated with severe HPV lesions. In this review, we describe clinical, immunological, and genetic patterns of IEI related to severe HPV cutaneous infections and propose an algorithm for diagnosis of IEI with severe warts associated, or not, with lymphopenia.
Identifiants
pubmed: 36014978
pii: pathogens11080857
doi: 10.3390/pathogens11080857
pmc: PMC9414374
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI143810
Pays : United States
Références
Arch Dermatol. 1963 Mar;87:306-10
pubmed: 13933441
Dermatology. 1996;193(4):318-20
pubmed: 8993956
Front Immunol. 2018 Feb 09;9:203
pubmed: 29479355
Virology. 2010 May 25;401(1):70-9
pubmed: 20206957
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
Hum Mol Genet. 2015 Dec 20;24(25):7361-72
pubmed: 26476407
Blood. 2012 Apr 12;119(15):3450-7
pubmed: 22294732
J Allergy Clin Immunol. 2012 Nov;130(5):1030-48
pubmed: 23036745
J Clin Invest. 2012 Sep;122(9):3239-47
pubmed: 22850876
BMJ Clin Evid. 2009 Sep 24;2009:
pubmed: 21726478
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1568-1577
pubmed: 30716504
J Exp Med. 2016 Oct 17;213(11):2413-2435
pubmed: 27647349
PLoS One. 2012;7(8):e44010
pubmed: 22952854
Cell. 2021 Jul 8;184(14):3812-3828.e30
pubmed: 34214472
Curr Opin Immunol. 2021 Oct;72:277-285
pubmed: 34364035
J Allergy Clin Immunol. 2016 Mar;137(3):879-88.e2
pubmed: 26476480
J Clin Immunol. 2015 Feb;35(2):189-98
pubmed: 25627830
Bull Acad Natl Med. 2010 Jun;194(6):923-40; discussion 941
pubmed: 21513129
Front Microbiol. 2018 Jun 12;9:1222
pubmed: 29946305
Aust Fam Physician. 2011 Jan-Feb;40(1-2):40-2
pubmed: 21301692
J Invest Dermatol. 2022 May;142(5):1265-1269
pubmed: 34843682
Hum Genet. 2020 Jun;139(6-7):919-939
pubmed: 32435828
Orphanet J Rare Dis. 2018 Nov 26;13(1):213
pubmed: 30477583
J Exp Med. 2018 Sep 3;215(9):2289-2310
pubmed: 30068544